Stromal Injury and Clonal Adaptation in Myelodysplasia
- Determine abnormal stromal function in patients with acute myeloid leukemia (AML),
myelodysplastic syndromes (MDS), or Fanconi anemia; in patients who were exposed to
alkylating agents; and in healthy volunteers.
- Determine whether clonal progenitors from patients with secondary AML or MDS are
resistant to selected extracellular apoptotic cues.
- Determine whether stromal function in patients with secondary AML or MDS is more
aberrant than stromal function in patients with primary AML or MDS.
- Determine whether cytotoxic agents known to induce secondary MDS or AML influence the
supportive function of the bone marrow stroma.
- Determine whether cytoprotective agents reduce both cytotoxicity and genotoxicity in
hematopoietic progenitor cells and stromal cells.
OUTLINE: Patients and healthy volunteers undergo bone marrow sample collection. Progenitor
cells are grown in culture. Cell survival is quantified by flow cytometric and cytogenetic
analysis, sister chromatid exchange, and FISH for chromosome 11 changes (for
etoposide-exposed samples only).
PROJECTED ACCRUAL: A total of 24 patients and healthy volunteers will be accrued for this
Observational Model: Case Control, Time Perspective: Prospective
Abnormal stromal function
Grover C. Bagby, MD
OHSU Knight Cancer Institute
United States: Federal Government
|OHSU Knight Cancer Institute||Portland, Oregon 97239|